Decoy Therapeutics (DCOY)
NASDAQ:DCOY
Want to see DCOY full AI Analyst Report?
Top Page
Decoy Therapeutics
(NASDAQ:DCOY)
Select Model
Select Model
Rating:43Neutral
Price Target:
$7.00
▲(20.48% Upside)
Action:Reiterated
Date:05/09/26
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn with shrinking equity). Technicals add further pressure with a broadly bearish trend and negative MACD. Valuation provides limited support given an uninformative P/E and no dividend yield, while the Nasdaq compliance event is a modest positive but does not offset the fundamental and trend risks.
Positive Factors
Low leverage / no debt
Zero reported debt provides durable financial flexibility for a pre‑commercial biotech. With no interest burden the company can prioritize R&D spending and partnership development without near‑term debt service constraints, easing financing timing while pursuing clinical milestones.
Negative Factors
Pre‑revenue with ongoing losses
The company remains pre‑commercial and cash‑consumptive, with sizable negative net income and operating cash flow. Persistent burn without product revenue means continued dependence on external financing, which can pressure strategy, timing of trials and increase dilution risk over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / no debt
Zero reported debt provides durable financial flexibility for a pre‑commercial biotech. With no interest burden the company can prioritize R&D spending and partnership development without near‑term debt service constraints, easing financing timing while pursuing clinical milestones.
Read all positive factors
Decoy Therapeutics (DCOY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.88M
Dividend YieldN/A
Average Volume (3M)356.88K
Price to Earnings (P/E)―
Beta (1Y)1.66
Revenue GrowthN/A
EPS Growth86.68%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding531,968
10 Day Avg. Volume434,140
30 Day Avg. Volume356,875
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-0.78
Enterprise Value/Market Cap-1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.46
Enterprise Value/Ebitda0.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Decoy Therapeutics Business Overview & Revenue Model
Company Description
Decoy Therapeutics, Inc. is a preclinical-stage biotechnology company that is leveraging machine learning and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that tar...
Decoy Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -8.52M | -8.52M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -13.20M | -12.61M | -5.73M | -12.88M | -22.97M | -12.79M |
| Net Income | -13.03M | -12.52M | -5.58M | -12.54M | -31.61M | -12.77M |
Balance Sheet | ||||||
| Total Assets | 8.42M | 11.06M | 3.02M | 6.59M | 14.65M | 40.83M |
| Cash, Cash Equivalents and Short-Term Investments | 7.82M | 10.71M | 2.43M | 5.90M | 12.11M | 29.21M |
| Total Debt | 0.00 | 0.00 | 221.87K | 289.64K | 0.00 | 0.00 |
| Total Liabilities | 4.55M | 5.17M | 1.51M | 1.30M | 4.27M | 2.11M |
| Stockholders Equity | 3.88M | 5.89M | 1.51M | 5.29M | 10.38M | 38.72M |
Cash Flow | ||||||
| Free Cash Flow | -6.53M | -4.83M | -4.53M | -12.85M | -19.10M | -10.20M |
| Operating Cash Flow | -6.53M | -4.83M | -4.53M | -12.85M | -17.60M | -10.20M |
| Investing Cash Flow | 764.74K | 764.74K | 0.00 | 0.00 | -1.50M | 0.00 |
| Financing Cash Flow | 11.79M | 12.34M | 1.06M | 6.64M | 1.99M | 28.30M |
Decoy Therapeutics Technical Analysis
Positive
5.81
Price Trends
6.13
Positive
7.51
Negative
24.47
Negative
Market Momentum
-0.04
Negative
68.47
Neutral
85.48
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DCOY, the sentiment is Positive. The current price of 5.81 is above the 20-day moving average (MA) of 5.56, below the 50-day MA of 6.13, and below the 200-day MA of 24.47, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 68.47 is Neutral, neither overbought nor oversold. The STOCH value of 85.48 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DCOY.
Decoy Therapeutics Risk Analysis
Decoy Therapeutics disclosed 46 risk factors in its most recent earnings report. Decoy Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Decoy Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.48M | -0.04 | -63.03% | ― | ― | 88.07% | |
44 Neutral | $1.60M | -0.20 | ― | ― | 99.48% | -474.47% | |
43 Neutral | $3.88M | -0.35 | -139.55% | ― | ― | 86.68% | |
| ― | $2.69M | -0.27 | -168.95% | ― | ― | 84.00% | |
| ― | $1.42M | -0.56 | -263.57% | ― | -61.81% | 99.68% |
* Healthcare Sector Average
DCOY
Decoy Therapeutics
7.30
-131.39
-94.74%
BDRX
Biodexa Pharmaceuticals
3.28
-54.22
-94.30%
QCLS
Q/C Technologies
4.18
-13.11
-75.82%
SCNI
Scinai Immunotherapeutics
0.46
-2.30
-83.30%
OGEN
Oragenics
0.60
-5.10
-89.53%
ONCO
Onconetix
1.24
-306.89
-99.60%
Decoy Therapeutics Corporate Events
Regulatory Filings and ComplianceShareholder Meetings
Decoy Therapeutics Sets 2026 Annual Shareholder Meeting Date
Neutral
May 19, 2026
On May 12, 2026, Decoy Therapeutics Inc.’s board set July 14, 2026, as the date for its 2026 Annual Meeting of Stockholders and designated May 22, 2026, as the record date for determining which investors may receive notice and vote. The comp...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Decoy Therapeutics Regains Nasdaq Compliance After Reverse Split
Positive
Apr 2, 2026
Decoy Therapeutics has regained compliance with Nasdaq’s minimum bid price requirement after a period of deficiency that began with a notice on December 31, 2025, when its shares traded below $1.00 for 30 consecutive business days. Following...
Delistings and Listing ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split
Decoy Therapeutics Announces Reverse Stock Split to Maintain Listing
Neutral
Mar 5, 2026
Decoy Therapeutics Inc., a preclinical-stage biopharmaceutical company focused on AI-enabled peptide conjugate therapeutics for respiratory viruses and gastrointestinal cancers, has built a diversified funding base from institutional investors and...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.